Construction and Validation of a Diagnostic Model for Predicting Molecular Residual Disease and Recurrence of Cervical Cancer Based on Circulating Tumor HPV
NCT06456112 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 83
Last updated 2024-07-01
Summary
Systematic evaluation of the value of molecular residual lesions of cervical cancer based on circulating tumor HPV in the prognostic evaluation and recurrence monitoring of cervical cancer patients.
Conditions
Sponsors & Collaborators
-
Anhui Provincial Hospital
lead OTHER_GOV
Principal Investigators
-
Ying Zhou, MD · The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-01
- Primary Completion
- 2026-07-30
- Completion
- 2026-07-30
Countries
- China
Study Locations
More Related Trials
-
Clinical Evaluation of Detection of High Risk HPV in Urine
NCT05210348 ·Status: UNKNOWN
-
Genetic Mutation in Recurrent Cervical Cancer
NCT04191226 ·Status: UNKNOWN
-
Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy
NCT05950087 ·Status: RECRUITING
-
The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis
NCT00728871 ·Status: UNKNOWN ·Phase: NA
-
Discovery of HPV T Cell Epitopes and Development of Multi-epitope Vaccines
NCT07077980 ·Status: NOT_YET_RECRUITING
-
Low-Cost Molecular Cervical Cancer Screening Study
NCT01231945 ·Status: COMPLETED
-
ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)
NCT06730412 ·Status: COMPLETED
-
Cervical Cancer Screening Strategies
NCT05309122 ·Status: UNKNOWN
-
Assessment of Prognosis Using Peripheral Blood Circulating Tumor DNA in Patients With Cervical Cancer
NCT05602831 ·Status: UNKNOWN
-
HPV Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma
NCT03742869 ·Status: UNKNOWN
-
The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer
NCT06283875 ·Status: NOT_YET_RECRUITING
-
Retrospective Study of the Relationship Between Human Papillomavirus Genotype and Cervical Epithelial Lesions
NCT00872937 ·Status: UNKNOWN
-
Cervical Cancer Screening with NGS-HPV Technology Based on Menstrual Blood
NCT06082765 ·Status: RECRUITING
-
Dynamic Monitoring of ctDNA and HPV DNA in Plasma for the Early Prediction of Recurrence After Cervical Cancer Surgery
NCT06420427 ·Status: RECRUITING
-
The Standard Management of HPV Infection
NCT03577925 ·Status: UNKNOWN
-
Third-Generation Nanopore HPV Integration Site for Precise Prediction of Cervical Cancer Prognosis
NCT06644677 ·Status: COMPLETED
-
A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer
NCT06039982 ·Status: NOT_YET_RECRUITING
-
DNA Methylation and the Increased Risk of Cervical Cancer Development
NCT06859151 ·Status: NOT_YET_RECRUITING
-
A Multicenter Cohort Study of HPV Viral Load in Predicting the Postoperative Recurrence of HSIL
NCT05282745 ·Status: RECRUITING
-
MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy
NCT06197126 ·Status: NOT_YET_RECRUITING
-
Mechanisms and Biomarkers for Tumor Immunogenicity Modulation in Cervical Cancer
NCT05188716 ·Status: COMPLETED
-
All-cause and Diseases-specific Mortality of High-risk HPV Infection
NCT06631495 ·Status: NOT_YET_RECRUITING
-
Innovation for Standard Identification of Insertional HPV Mutations and of Target Therapeutic Genes in Cervical Cancer: Towards Development of Personalized Biomarkers in Clinical Oncology (PAIR HPV)
NCT02554565 ·Status: TERMINATED ·Phase: NA
-
HPV E6/E7 mRNA Versus HPV DNA as Triage for Cervical Cancer Screening
NCT02116920 ·Status: UNKNOWN
-
Clinical Trial for Registration of HPV Nucleic Acid Genotyping Assay Kit
NCT04461678 ·Status: COMPLETED ·Phase: NA